DYN

Dyne Therapeutics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · dyne-tx.com

$17.71

Mkt Cap $2.9B

52w Low $8.06 57.0% of range 52w High $25.00

50d MA $17.86 200d MA $16.56

P/E (TTM) -5.0x

EV/EBITDA -3.7x

P/B 2.3x

Debt/Equity 0.0x

ROE -45.9%

P/FCF -6.2x

RSI (14) —

ATR (14) —

Beta 1.28

50d MA $17.86

200d MA $16.56

Avg Volume 2.1M

About

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORC…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 2, 2026	AMC	-0.74	-0.76	-2.7%	16.15	-4.1%	-9.6%	-5.7%	-5.9%	-8.0%	+9.5%	—
Nov 5, 2025	AMC	-0.81	-0.76	+6.2%	20.90	+0.8%	-12.9%	-12.2%	-11.4%	-5.9%	-11.0%	—
Jul 28, 2025	AMC	-0.99	-0.97	+2.0%	9.31	+2.0%	-1.2%	+6.4%	+5.8%	+7.9%	+10.1%	—
May 8, 2025	AMC	-0.88	-1.05	-19.3%	11.30	+1.2%	+1.0%	+11.2%	+7.1%	+3.5%	+3.9%	—
Feb 27, 2025	AMC	-0.92	-0.88	+4.3%	13.17	-0.5%	+3.3%	-6.5%	-9.7%	-7.5%	-7.1%	—
Nov 12, 2024	AMC	-0.71	-0.96	-35.2%	29.33	-0.7%	+16.4%	+3.3%	-3.2%	+0.0%	+1.2%	—
Aug 12, 2024	AMC	-0.72	-0.70	+2.8%	43.07	+2.7%	+1.3%	+1.9%	+6.2%	+5.4%	+7.1%	—
May 2, 2024	AMC	-0.81	-0.81	+0.0%	26.00	+0.0%	+0.3%	+1.0%	-1.3%	-1.2%	-0.2%	—
Mar 5, 2024	AMC	-0.92	-1.09	-18.5%	25.87	+4.3%	+3.5%	+2.2%	-2.7%	-1.2%	+4.8%	—
Oct 30, 2023	AMC	-0.86	-0.99	-15.1%	7.32	-1.8%	-3.7%	-0.3%	-2.3%	+12.4%	+11.5%	—
Aug 3, 2023	AMC	-0.81	-1.08	-33.3%	11.50	-0.8%	+0.4%	+0.5%	-13.7%	-8.0%	-5.0%	—
May 11, 2023	AMC	-0.77	-0.78	-1.3%	13.60	+0.4%	-1.2%	+0.7%	-1.8%	-0.2%	-3.2%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 9	Chardan Capital	Maintains	Buy → Buy	—	$14.86	$15.27	+2.8%	+19.0%	+33.1%	+34.5%	+21.5%	+20.6%
Mar 3	Morgan Stanley	Maintains	Overweight → Overweight	—	$16.15	$15.49	-4.1%	-9.6%	-5.7%	-5.9%	-8.0%	+9.5%
Mar 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$16.15	$15.49	-4.1%	-9.6%	-5.7%	-5.9%	-8.0%	+9.5%
Mar 3	Chardan Capital	Maintains	Buy → Buy	—	$16.15	$15.49	-4.1%	-9.6%	-5.7%	-5.9%	-8.0%	+9.5%
Jan 20	JP Morgan	Maintains	Neutral → Neutral	—	$16.70	$16.52	-1.1%	-0.7%	+4.8%	+8.3%	+7.8%	+7.8%
Dec 15	Evercore ISI	Maintains	Outperform → Outperform	—	$19.27	$19.31	+0.2%	+1.7%	+1.5%	-1.9%	-3.7%	+3.0%
Dec 11	Stifel	Maintains	Buy → Buy	—	$19.69	$20.05	+1.8%	-1.4%	-2.1%	-0.5%	-0.7%	-4.0%
Dec 10	Oppenheimer	Upgrade	Perform → Outperform	—	$18.44	$19.57	+6.1%	+6.8%	+5.3%	+4.5%	+6.2%	+6.0%
Dec 9	Morgan Stanley	Maintains	Overweight → Overweight	—	$22.20	$21.41	-3.6%	-16.9%	-11.3%	-12.5%	-13.2%	-11.8%
Dec 9	Chardan Capital	Maintains	Buy → Buy	—	$22.20	$21.41	-3.6%	-16.9%	-11.3%	-12.5%	-13.2%	-11.8%
Dec 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$20.28	$21.59	+6.5%	+9.5%	-9.1%	-2.9%	-4.2%	-5.0%
Nov 14	JP Morgan	Maintains	Neutral → Neutral	—	$18.83	$18.34	-2.6%	-0.2%	+7.5%	+11.3%	+9.4%	+6.9%
Nov 12	Oppenheimer	Maintains	Perform → Perform	—	$19.67	$19.41	-1.3%	-5.4%	-4.3%	-4.5%	+2.9%	+6.6%
Nov 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$20.90	$21.06	+0.8%	-12.9%	-12.2%	-11.4%	-5.9%	-11.0%
Nov 6	RBC Capital	Maintains	Outperform → Outperform	—	$20.90	$21.06	+0.8%	-12.9%	-12.2%	-11.4%	-5.9%	-11.0%
Oct 10	Oppenheimer	Downgrade	Outperform → Perform	—	$14.68	$14.13	-3.7%	-4.3%	-4.4%	+5.2%	+12.6%	+11.9%
Aug 25	Raymond James	Upgrade	Outperform → Strong Buy	—	$12.58	$13.55	+7.7%	+3.3%	+6.4%	+8.4%	+9.3%	+7.2%
Aug 6	Oppenheimer	Maintains	Outperform → Outperform	—	$10.47	$10.23	-2.3%	+10.7%	+6.9%	+6.6%	+7.4%	+11.0%
Jul 31	Stifel	Maintains	Buy → Buy	—	$9.91	$9.80	-1.1%	-0.6%	+1.4%	+3.4%	+5.7%	+17.0%
Jul 29	Chardan Capital	Maintains	Buy → Buy	—	$9.31	$9.50	+2.0%	-1.2%	+6.4%	+5.8%	+7.9%	+10.1%
Jul 29	Raymond James	Maintains	Outperform → Outperform	—	$9.31	$9.50	+2.0%	-1.2%	+6.4%	+5.8%	+7.9%	+10.1%
Jul 29	RBC Capital	Maintains	Outperform → Outperform	—	$9.31	$9.50	+2.0%	-1.2%	+6.4%	+5.8%	+7.9%	+10.1%
Jul 15	JP Morgan	Maintains	Neutral → Neutral	—	$8.91	$9.04	+1.5%	-7.1%	+4.7%	+5.5%	+1.2%	+2.9%
Jun 18	Baird	Maintains	Outperform → Outperform	—	$10.86	$10.79	-0.6%	-0.7%	-5.0%	-6.4%	-2.1%	-4.1%
Jun 18	Guggenheim	Maintains	Buy → Buy	—	$10.86	$10.79	-0.6%	-0.7%	-5.0%	-6.4%	-2.1%	-4.1%
Jun 17	Chardan Capital	Maintains	Buy → Buy	—	$13.82	$12.51	-9.5%	-21.4%	-22.0%	-25.3%	-26.5%	-23.1%
May 9	Chardan Capital	Maintains	Buy → Buy	—	$11.30	$11.44	+1.2%	+1.0%	+11.2%	+7.1%	+3.5%	+3.9%
May 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.30	$11.44	+1.2%	+1.0%	+11.2%	+7.1%	+3.5%	+3.9%
Mar 21	JP Morgan	Maintains	Neutral → Neutral	—	$12.26	$12.14	-1.0%	-1.5%	+1.1%	-7.0%	-8.2%	-3.8%
Mar 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$12.05	$12.46	+3.4%	+2.2%	+4.4%	+2.9%	+1.7%	+0.2%
Mar 17	Chardan Capital	Maintains	Buy → Buy	—	$12.05	$12.46	+3.4%	+2.2%	+4.4%	+2.9%	+1.7%	+0.2%
Feb 28	Piper Sandler	Maintains	Overweight → Overweight	—	$13.17	$13.10	-0.5%	+3.3%	-6.5%	-9.7%	-7.5%	-7.1%
Feb 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.17	$13.10	-0.5%	+3.3%	-6.5%	-9.7%	-7.5%	-7.1%
Feb 28	Chardan Capital	Maintains	Buy → Buy	—	$13.17	$13.10	-0.5%	+3.3%	-6.5%	-9.7%	-7.5%	-7.1%
Jan 24	Guggenheim	Maintains	Buy → Buy	—	$13.69	$13.72	+0.2%	+0.2%	-0.1%	-1.7%	-1.1%	+3.3%
Jan 14	RBC Capital	Maintains	Outperform → Outperform	—	$15.29	$15.75	+3.0%	-1.9%	+1.6%	-3.4%	-7.6%	-4.8%
Jan 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.87	$15.80	-0.4%	-3.7%	-5.5%	-2.1%	-6.9%	-11.0%
Jan 10	Chardan Capital	Maintains	Buy → Buy	—	$23.05	$20.00	-13.2%	-31.1%	-33.7%	-34.9%	-32.6%	-35.9%
Jan 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$23.05	$20.00	-13.2%	-31.1%	-33.7%	-34.9%	-32.6%	-35.9%
Nov 13	Chardan Capital	Maintains	Buy → Buy	—	$29.33	$29.12	-0.7%	+16.4%	+3.3%	-3.2%	+0.0%	+1.2%
Nov 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$29.33	$29.12	-0.7%	+16.4%	+3.3%	-3.2%	+0.0%	+1.2%
Oct 24	JP Morgan	Downgrade	Overweight → Neutral	—	$32.36	$31.33	-3.2%	-3.9%	-5.0%	-4.9%	-6.6%	-9.8%
Sep 23	Piper Sandler	Maintains	Overweight → Overweight	—	$36.59	$36.64	+0.1%	-5.4%	-8.7%	-4.7%	-5.4%	-7.5%
Sep 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$31.94	$31.88	-0.2%	+5.7%	+5.4%	+3.4%	+1.7%	+1.5%
Sep 3	Oppenheimer	Maintains	Outperform → Outperform	—	$46.09	$27.77	-39.7%	-30.7%	-26.8%	-27.0%	-28.3%	-29.6%
Aug 16	Stifel	Maintains	Buy → Buy	—	$45.74	$45.36	-0.8%	-0.8%	+0.8%	+2.4%	+2.8%	-0.5%
Aug 15	Guggenheim	Maintains	Buy → Buy	—	$43.88	$45.01	+2.6%	+4.2%	+3.4%	+5.1%	+6.7%	+7.2%
Aug 14	Morgan Stanley	Maintains	Overweight → Overweight	—	$43.64	$43.89	+0.6%	+0.6%	+4.8%	+4.0%	+5.7%	+7.3%
Aug 13	Piper Sandler	Maintains	Overweight → Overweight	—	$43.07	$44.24	+2.7%	+1.3%	+1.9%	+6.2%	+5.4%	+7.1%
Aug 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$43.07	$44.24	+2.7%	+1.3%	+1.9%	+6.2%	+5.4%	+7.1%

Recent Filings

8-K

Dyne Therapeutics, Inc. -- 8-K Filing

Dyne Therapeutics reported 2025 financial results and highlighted progress in its clinical-stage pipeline for treating genetically driven neuromuscular diseases, positioning the biotech company for upcoming regulatory submissions.

Mar 2

Data updated apr 25, 2026 6:12am · Source: massive.com